<DOC>
	<DOCNO>NCT01348451</DOCNO>
	<brief_summary>This first-in-human trial spinal derive stem cell transplant spinal cord patient Amyotrophic Lateral Sclerosis ( ALS ) . The goal study see cell procedure transplant safe .</brief_summary>
	<brief_title>Human Spinal Cord Derived Neural Stem Cell Transplantation Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>These stem cell call Human Spinal Stem Cells ( HSSC ) engineer spinal cord single fetus electively abort 8 week gestation . The tissue obtain mother 's consent . The cell transplant ALS patient 's spinal cord laminectomy , operation remove bone surround spine . After spinal cord expose , device manufacture purpose mount onto patient hold syringe fill cell . The syringe needle attach needle enter spinal cord specify area . The device minimize trauma spinal cord needle make puncture precise steady inject material slow steady speed . ALS universally fatal neurodegenerative condition cause weakness lead paralysis death . Life expectancy 2-5 year . The cause unknown effective treatment . Previous research show autopsy , ALS patient find increased level amino acid glutamate accumulate brain spinal cord . This increase think caused decrease glutamate transporter normally `` clean '' glutamate cell . Because HSSC human origin , transplantation handle way like organ transplant patient receive immunosuppressive medication prevent rejection cell . Right immediately surgery patient receive infusion drug call basiliximab . After surgery take prednisone taper medication one month . They also give two immunosuppressive agent , tacrolimus mycophenolate mofetil surgery expect patient take drug rest life .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Have ability understand requirement study , provide write informed consent , understand provide write authorization use disclosure Protected Health Information ( PHI ) [ per Health Insurance Portability Accountability Act ( HIPAA ) Privacy Ruling ] comply study procedure . 2 . Subjects sporadic familial ALS diagnose laboratorysupported probable , probable definite accord World Federation Neurology El Escorial Criteria ( Appendix A ) , base examination site PI . 3 . Age 18 year old . 4 . Females must negative serum pregnancy test practice acceptable method contraception nonchildbearing potential ( postmenopausal least 2 year surgically sterile [ hysterectomy , oophorectomy surgical sterilization ] ) . 5 . Geographic accessibility study center ability travel clinic study visit . 6 . Presence willing able caregiver . 7 . Medically able undergo lumbar cervical laminectomy determine Investigator , surgeon anesthesiologist . 8 . Medically able tolerate immunosuppression regimen consist basiliximab , tacrolimus , mycophenolate mofetil , methylprednisolone determine site Investigator . 9 . Agrees visit schedule outline informed consent . 10 . Not take riluzole ( Rilutek® ) stable dose ≥30 day . 11 . All required vaccination current : tetanus/diptheria ( TDAP ) , herpes zoster/shingles ( Vostavax® : within last 10 year must prior surgery ) , pneumonia ( Pneumovax® ) , seasonal/H1N1 flu vaccine ( appropriate season ) Groups BE . 1 . Etiology paraplegia weakness due cause ALS spinal ischemia , traumatic spinal injury , traumatic brain injury , multiple sclerosis , cerebral stroke , cerebral palsy , infection . 2 . VC &lt; 60 % predict normal standard nomogram time screen VC &lt; 50 % predict normal measured supine age time surgery . 3 . Current peak Panel Reactive Antibody ( PRA ) due alloantibody &gt; 20 % receive first allograft . 4 . Any known immunodeficiency syndrome . 5 . Receipt investigational drug , device biologic within 30 day surgery . 6 . Any concomitant medical disease condition limit safety participate : Coagulopathy Active uncontrolled infection Hypotension require vasopressor therapy Previous spinal surgery site plan transplantation except anterior cervical dissection fusion ( ACDF ) Skin breakdown site surgery Malignancy ( except nonmelanoma skin cancer ) Primary secondary immune deficiency Spinal stenosis . 7 . Creatinine &gt; 1.5 , liver function test ( SGOT/SGPT , Bilirubin , Alk Phos ) &gt; 2x upper limit normal , hematocrit/hemoglobin &lt; 30/10 , total WBC &lt; 4000 , uncontrolled hypertension ( define systolic &gt; 180 diastolic &gt; 100 ) uncontrolled diabetes ( define hemoglobin A1C &gt; 8 ) , evidence GI bleeding hemoccult test , positive tuberculosis ( TB test : PPD/Mantoux ) , hepatitis B C , human immunodeficiency virus ( HIV ) . 8 . Presence follow condition : Current drug abuse alcoholism Unstable medical condition Unstable psychiatric illness include psychosis untreated major depression within 90 day screen Positive blood test hepatitis B C. 9 . Any condition site PI feel may interfere participation study . 10 . Any condition surgeon feel may pose complication surgery . 11 . Known hypersensitivity basiliximab , tacrolimus , mycophenolate mofetil , methylprednisolone . 12 . Inability provide inform consent determine screen protocol . 13 . Inadequate family caregiver support determine site PI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Human spinal cord derive neural stem cell transplantation</keyword>
	<keyword>ALS</keyword>
</DOC>